{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:58:50Z","timestamp":1789675130344,"version":"4.0.1"},"reference-count":25,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Detailed diagnostic features of acute myeloid leukemia in Down syndrome are lacking, leading to potential misdiagnoses as standard acute myeloid leukemia occurring in patients with Down syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To evaluate diagnostic features of acute myeloid leukemia and myelodysplastic syndrome in patients with Down syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>Diagnostic bone marrow samples from 163 patients enrolled in the Children's Oncology Group study AAML0431 were evaluated by using central morphologic review and institutional immunophenotyping. Results were compared to overall survival, event-free survival, GATA1 mutation status, cytogenetics, and minimal residual disease results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>Sixty myelodysplastic syndrome and 103 acute myeloid leukemia samples were reviewed. Both had distinctive features compared to those of patients without Down syndrome. They showed megakaryocytic and erythroid but little myeloid dysplasia, and marked megakaryocytic hyperplasia with unusual megakaryocyte morphology. In acute myeloid leukemia cases, megakaryoblastic differentiation of blasts was most common (54 of 103, 52%); other cases showed erythroblastic (11 of 103, 11%), mixed erythroid\/megakaryoblastic (20 of 103, 19%), or no differentiation (10 of 103, 10%). Myelodysplastic syndrome and acute myeloid leukemia cases had similar event-free survival and overall survival. Leukemic subgroups showed interesting, but not statistically significant, trends for survival and minimal residual disease. Cases with institutional diagnoses of French American British M1-5 morphology showed typical features of Down syndrome disease, with survival approaching that of other cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>Myelodysplastic syndrome and acute myeloid leukemia in Down syndrome display features that allow discrimination from standard cases of disease. These distinctions are important for treatment decisions, and for understanding disease pathogenesis. We propose specific diagnostic criteria for Down syndrome\u2013related subtypes of acute myeloid leukemia and myelodysplastic syndrome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2018-0526-oa","type":"journal-article","created":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T11:39:18Z","timestamp":1566301158000},"page":"466-472","source":"Crossref","is-referenced-by-count":18,"title":["Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431"],"prefix":"10.5858","volume":"144","author":[{"given":"Kelley J.","family":"Mast","sequence":"first","affiliation":[{"name":"From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Drs Mast, Mosse, Jones, and Head); the Division of Hematology\/Oncology, Children's Hospital of Michigan, Wayne State University, Detroit (Dr Taub); the Department of Biostatistics, University of Southern California, Monrovia (Dr Alonzo and Mr Wang); the Division of Hematolog"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Taub","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Drs Mast, Mosse, Jones, and Head); the Division of Hematology\/Oncology, Children's Hospital of Michigan, Wayne State University, Detroit (Dr Taub); the Department of Biostatistics, University of Southern California, Monrovia (Dr Alonzo and Mr Wang); the Division of Hematolog"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Alonzo","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Drs Mast, Mosse, Jones, and Head); the Division of Hematology\/Oncology, Children's Hospital of Michigan, Wayne State University, Detroit (Dr Taub); the Department of Biostatistics, University of Southern California, Monrovia (Dr Alonzo and Mr Wang); the Division of Hematolog"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Gamis","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Drs Mast, Mosse, Jones, and Head); the Division of Hematology\/Oncology, Children's Hospital of Michigan, Wayne State University, Detroit (Dr Taub); the Department of Biostatistics, University of Southern California, Monrovia (Dr Alonzo and Mr Wang); the Division of Hematolog"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio A.","family":"Mosse","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Drs Mast, Mosse, Jones, and Head); the Division of Hematology\/Oncology, Children's Hospital of Michigan, Wayne State University, Detroit (Dr Taub); the Department of Biostatistics, University of Southern California, Monrovia (Dr Alonzo and Mr Wang); the Division of Hematolog"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad","family":"Mathew","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Drs Mast, Mosse, Jones, and Head); the Division of Hematology\/Oncology, Children's Hospital of Michigan, Wayne State University, Detroit (Dr Taub); the Department of Biostatistics, University of Southern California, Monrovia (Dr Alonzo and Mr Wang); the Division of Hematolog"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason N.","family":"Berman","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Drs Mast, Mosse, Jones, and Head); the Division of Hematology\/Oncology, Children's Hospital of Michigan, Wayne State University, Detroit (Dr Taub); the Department of Biostatistics, University of Southern California, Monrovia (Dr Alonzo and Mr Wang); the Division of Hematolog"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Cheng","family":"Wang","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Drs Mast, Mosse, Jones, and Head); the Division of Hematology\/Oncology, Children's Hospital of Michigan, Wayne State University, Detroit (Dr Taub); the Department of Biostatistics, University of Southern California, Monrovia (Dr Alonzo and Mr Wang); the Division of Hematolog"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heath M.","family":"Jones","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Drs Mast, Mosse, Jones, and Head); the Division of Hematology\/Oncology, Children's Hospital of Michigan, Wayne State University, Detroit (Dr Taub); the Department of Biostatistics, University of Southern California, Monrovia (Dr Alonzo and Mr Wang); the Division of Hematolog"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Campana","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Drs Mast, Mosse, Jones, and Head); the Division of Hematology\/Oncology, Children's Hospital of Michigan, Wayne State University, Detroit (Dr Taub); the Department of Biostatistics, University of Southern California, Monrovia (Dr Alonzo and Mr Wang); the Division of Hematolog"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Coustan-Smith","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Drs Mast, Mosse, Jones, and Head); the Division of Hematology\/Oncology, Children's Hospital of Michigan, Wayne State University, Detroit (Dr Taub); the Department of Biostatistics, University of Southern California, Monrovia (Dr Alonzo and Mr Wang); the Division of Hematolog"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana C.","family":"Raimondi","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Drs Mast, Mosse, Jones, and Head); the Division of Hematology\/Oncology, Children's Hospital of Michigan, Wayne State University, Detroit (Dr Taub); the Department of Biostatistics, University of Southern California, Monrovia (Dr Alonzo and Mr Wang); the Division of Hematolog"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Hirsch","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Drs Mast, Mosse, Jones, and Head); the Division of Hematology\/Oncology, Children's Hospital of Michigan, Wayne State University, Detroit (Dr Taub); the Department of Biostatistics, University of Southern California, Monrovia (Dr Alonzo and Mr Wang); the Division of Hematolog"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann K.","family":"Hitzler","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Drs Mast, Mosse, Jones, and Head); the Division of Hematology\/Oncology, Children's Hospital of Michigan, Wayne State University, Detroit (Dr Taub); the Department of Biostatistics, University of Southern California, Monrovia (Dr Alonzo and Mr Wang); the Division of Hematolog"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Head","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Drs Mast, Mosse, Jones, and Head); the Division of Hematology\/Oncology, Children's Hospital of Michigan, Wayne State University, Detroit (Dr Taub); the Department of Biostatistics, University of Southern California, Monrovia (Dr Alonzo and Mr Wang); the Division of Hematolog"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2019,8,20]]},"reference":[{"issue":"12","key":"2020081300422580300_i1543-2165-144-4-466-b01","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/bdra.20735","article-title":"Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006","volume":"88","author":"Parker","year":"2010","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"9199","key":"2020081300422580300_i1543-2165-144-4-466-b02","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(99)05264-2","article-title":"Risks of leukaemia and solid tumours in individuals with Down's syndrome","volume":"355","author":"Hasle","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"2020081300422580300_i1543-2165-144-4-466-b03","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2013-06-509463","article-title":"Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group","volume":"123","author":"Buitenkamp","year":"2014","journal-title":"Blood"},{"key":"2020081300422580300_i1543-2165-144-4-466-b04","unstructured":"Ries\n              LAG\n            , SmithMA, GurneyJG, et al, \n          eds. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute, SEER Program; 1999. NIH Pub. No. 99-4649."},{"issue":"3","key":"2020081300422580300_i1543-2165-144-4-466-b05","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0145-2126(94)90111-2","article-title":"and acute megakaryoblastic leukemia in Down's syndrome","volume":"18","author":"Zipursky","year":"1994","journal-title":"Leukemia Res"},{"key":"2020081300422580300_i1543-2165-144-4-466-b06","first-page":"142","article-title":"Myeloid proliferations related to Down syndrome","author":"Baumann","year":"2008","journal-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed"},{"issue":"1","key":"2020081300422580300_i1543-2165-144-4-466-b07","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.hoc.2009.11.009","article-title":"Acute leukemias in children with Down syndrome","volume":"24","author":"Zwaan","year":"2010","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"2020081300422580300_i1543-2165-144-4-466-b08","first-page":"608","article-title":"Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891","volume":"91","author":"Lange","year":"1998","journal-title":"Blood"},{"issue":"6","key":"2020081300422580300_i1543-2165-144-4-466-b09","doi-asserted-by":"crossref","first-page":"F503","DOI":"10.1136\/adc.2006.104638","article-title":"Haematology of Down syndrome","volume":"92","author":"Webb","year":"2007","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"5","key":"2020081300422580300_i1543-2165-144-4-466-b10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2353\/jmoldx.2009.080132","article-title":"Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology","volume":"11","author":"Xavier","year":"2009","journal-title":"J Mol Diagn"},{"issue":"7","key":"2020081300422580300_i1543-2165-144-4-466-b11","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood-2003-10-3383","article-title":"Natural history of GATA1 mutations in Down syndrome","volume":"103","author":"Ahmed","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2020081300422580300_i1543-2165-144-4-466-b12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2003-05-1556","article-title":"Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome","volume":"103","author":"Gurbuxani","year":"2004","journal-title":"Blood"},{"issue":"22","key":"2020081300422580300_i1543-2165-144-4-466-b13","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1182\/blood-2010-05-282426","article-title":"Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia","volume":"116","author":"Kanezaki","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2020081300422580300_i1543-2165-144-4-466-b14","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2002-12-3904","article-title":"Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis","volume":"101","author":"Mundschau","year":"2003","journal-title":"Blood"},{"issue":"11","key":"2020081300422580300_i1543-2165-144-4-466-b15","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1182\/blood-2003-01-0013","article-title":"GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome","volume":"101","author":"Hitzler","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2020081300422580300_i1543-2165-144-4-466-b16","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/pbc.25789","article-title":"Preserved high probability of overall survival with significant reduction of chemotherapy for myeloid leukemia in Down syndrome: a nationwide prospective study in Japan","volume":"63","author":"Taga","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"25","key":"2020081300422580300_i1543-2165-144-4-466-b17","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1182\/blood-2017-01-764324","article-title":"Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial","volume":"129","author":"Taub","year":"2017","journal-title":"Blood"},{"issue":"25","key":"2020081300422580300_i1543-2165-144-4-466-b18","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1182\/blood-2017-01-765057","article-title":"Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial","volume":"129","author":"Uffmann","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2020081300422580300_i1543-2165-144-4-466-b19","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/sj.leu.2405060","article-title":"Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML","volume":"22","author":"Hasle","year":"2008","journal-title":"Leukemia"},{"key":"2020081300422580300_i1543-2165-144-4-466-b20","unstructured":"Foucar\n              K\n            , McKennaRW, PetersonLAC, KroftSH. \n          In: Tumors of the Bone Marrow. Vol 24. Washington, DC: American Registry of Pathology; 2016:169\u2013202. AFIP Atlas of Tumor Pathology; series 4."},{"issue":"8","key":"2020081300422580300_i1543-2165-144-4-466-b21","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"key":"2020081300422580300_i1543-2165-144-4-466-b22","first-page":"793","article-title":"Myelodysplastic syndromes","author":"Hasserjian","year":"2017","journal-title":"Hematopathology. 2nd ed"},{"issue":"6","key":"2020081300422580300_i1543-2165-144-4-466-b23","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol"},{"issue":"9","key":"2020081300422580300_i1543-2165-144-4-466-b24","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1182\/blood.V80.9.2210.2210","article-title":"Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498","volume":"80","author":"Ravindranath","year":"1992","journal-title":"Blood"},{"issue":"6","key":"2020081300422580300_i1543-2165-144-4-466-b25","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1182\/blood-2013-07-515528","article-title":"GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity","volume":"123","author":"Spinner","year":"2014","journal-title":"Blood"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/144\/4\/466\/2500500\/arpa_2018-0526-oa.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/144\/4\/466\/2500500\/arpa_2018-0526-oa.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:40:14Z","timestamp":1764790814000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/144\/4\/article-p466.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,20]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,8,20]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2018-0526-oa","relation":{},"ISSN":["0003-9985","1543-2165"],"issn-type":[{"value":"0003-9985","type":"print"},{"value":"1543-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,20]]}}}